Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase 1b Study of SL-172154 (SIRPα-Fc-CD40L) Administered With Either Pegylated Liposomal Doxorubicin or Mirvetuximab Soravtansine in Subjects With Platinum-Resistant Ovarian Cancers

NCT05483933 is registered in ClinicalTrials.gov with Shattuck Labs, Inc. as lead sponsor.

NCT NCT05483933
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05483933 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase 1b Study of SL-172154 (SIRPα-Fc-CD40L) Administered With Either Pegylated Liposomal Doxorubicin or Mirvetuximab Soravtansine in Subjects With Platinum-Resistant Ovarian Cancers
Lead sponsor
Shattuck Labs, Inc.
Phase
Phase 1
Overall status
Completed
Start date
August 18, 2022
Completion date
February 7, 2025
Enrollment
86 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

epithelial ovarian cancer, fallopian tube cancer, ovarian cancer, platinum-resistant fallopian tube carcinoma, platinum-resistant ovarian cancer, platinum-resistant primary peritoneal carcinoma, primary peritoneal carcinoma